633 research outputs found
Solid hulls and cores of weighted H-infinity-spaces
No full text[EN] We determine the solid hull and solid core of weighted Banach spaces H-upsilon(infinity) of analytic functions functions f such that upsilon vertical bar f vertical bar is bounded, both in the case of the holomorphic functions on the disc and on the whole complex plane, for a very general class of radial weights upsilon. Precise results are presented for concrete weights on the disc that could not be treated before. It is also shown that if H-upsilon(infinity) is solid, then the monomials are an (unconditional) basis of the closure of the polynomials in H-upsilon(infinity). As a consequence H-upsilon(infinity) does not coincide with its solid hull and core in the case of the disc. An example shows that this does not hold for weighted spaces of entire functions.The research of Bonet was partially supported by the project MTM2016-76647-P. The research of Taskinen was partially supported by the Vaisala Foundation of the Finnish Academy of Sciences and Letters.Bonet Solves, JA.; Lusky, W.; Taskinen, J. (2018). Solid hulls and cores of weighted H-infinity-spaces. Revista Matemática Complutense. 31(3):781-804. https://doi.org/10.1007/s13163-018-0265-6S781804313Anderson, J.M., Shields, A.L.: Coefficient multipliers of Bloch functions. Trans. Am. Math. Soc. 224, 255–265 (1976)Bennet, G., Stegenga, D.A., Timoney, R.M.: Coefficients of Bloch and Lipschitz functions. Ill. J. Math. 25, 520–531 (1981)Bierstedt, K.D., Bonet, J., Galbis, A.: Weighted spaces of holomorphic functions on bounded domains. Mich. Math. J. 40, 271–297 (1993)Bierstedt, K.D., Bonet, J., Taskinen, J.: Associated weights and spaces of holomorphic functions. Stud. Math. 127, 137–168 (1998)Blasco, O., Galbis, A.: On Taylor coefficients of entire functions integrable against exponential weights. Math. Nachr. 223, 5–21 (2001)Blasco, O., Pavlovic, M.: Coefficient multipliers on Banach spaces of analytic functions. Rev. Mat. Iberoam. 27, 415–447 (2011)Bonet, J., Taskinen, J.: Solid hulls of weighted Banach spaces of entire functions. Rev. Mat. Iberoam. 34, 593–608 (2018)Bonet, J., Taskinen, J.: Solid hulls of weighted Banach spaces of analytic functions on the unit disc with exponential weights. Ann. Acan. Sci. Fenn. Math. 43, 521–530 (2018)Constantin, O., Peláez, J.A.: Boundedness of the Bergman projection on L p -spaces with exponential weights. Bull. Sci. Math. 139(3), 245–268 (2015)Dostanić, M.R.: Multipliers in the space of analytic functions with exponential mean growth. Asymptot. Anal. 65(3–4), 191–201 (2009)Dostanić, M.-R.: Integration operators on Bergman spaces with exponential weight. Rev. Mat. Iberoam. 23(2), 421–436 (2007)Jevtić, M., Pavlović, M.: On the solid hull of the Hardy-Lorentz space. Publ. Inst. Math. (Beogr.) (N.S.) 85(99), 55–61 (2009)Jevtić, M., Vukotić, D., Arsenović, M.: Taylor Coefficients and Coefficient Multipliers of Hardy and Bergman-Type Spaces. RSME Springer Series, vol. 2. Springer, Berlin (2016)Lindenstrauss, J., Tzafriri, L.: Classical Banach Spaces I. Springer, Berlin (1977)Lusky, W.: On the Fourier series of unbounded harmonic functions. J. Lond. Math. Soc. 2(61), 568–580 (2000)Lusky, W.: On the isomorphism classes of weighted spaces of harmonic and holomorphic functions. Stud. Math. 175, 19–45 (2006)Pau, J., Peláez, J.A.: Volterra type operators on Bergman spaces with exponential weights. Contemp. Math. 561, 239–252. Topics in complex analysis and operator theory. American Mathematical Society, Providence (2012)Pavlović, M.: On harmonic conjugates with exponential mean growth. Czech. Math. J. 49, 733–742 (1999)Pavlović, M.: Function Classes on the Unit Disc: An Introduction. De Gruyter Studies in Mathematics, vol. 52, p. 449. De Gruyter, Berlin (2014)Peláez, J.A., Rättyä, J.: Weighted Bergman Spaces Induced by Rapidly Increasing Weights, vol. 227, no. 1066, pp. vi+124. American Mathematical Society (2014)Shields, A.L., Williams, D.L.: Bounded projections, duality and multipliers in spaces of analytic functions. Trans. Am. Math. Soc. 162, 287–302 (1971
Serum cholesterol levels in neutropenic patients with fever
No full textHypocholesterolemia, which often accompanies infectious diseases has been suggested to serve as a prognostic marker in hospitalized patients. Even though patients with chemotherapyinduced leukopenia are at high risk of infection and mortality, only limited information is available on serum cholesterol levels in these patients. We therefore measured serum cholesterol levels in 17 patients with hematological malignancies during chemotherapyinduced neutropenia and correlated it with clinical outcome. Patients with fever (>38.5 degreesC) showed a significant decrease in serum cholesterol levels within 24 hours. Eight days after onset of the fever nonsurvivors had significantly lower serum cholesterol levels (median 2.09 mmol/l, range 0.492.79, n=6) compared to survivors (median 3.23 mmol/l, range 1.684.86, n=11). Cholesterol levels in survivors returned to baseline levels at the time of discharge from the hospital. At the onset of fever, serum levels of inflammatory cytokines interleukin-6, tumor necrosis factor (TNF) and soluble TNF receptors p55 and p75 were elevated in all patients, but only TNF and TNF receptor p75 levels were significantly different in survivors and nonsurvivors. Our data suggest that a decrease in serum cholesterol levels is a prognostic marker in neutropenic patients with fever. Release of inflammatory cytokines may in part be responsible for hypocholesterolemia in these patients
PPAR alpha: an emerging therapeutic target in diabetic microvascular damage
No full textThe global pandemic of diabetes mellitus portends an alarming rise in the prevalence of microvascular complications, despite advanced therapies for hyperglycemia, hypertension and dyslipidemia. Peroxisome proliferator-activated receptor alpha (PPAR alpha) is expressed in organs affected by diabetic microvascular disease (retina, kidney and nerves), and its expression is regulated specifically in these tissues. Experimental evidence suggests that PPAR alpha activation attenuates or inhibits several mediators of vascular damage, including lipotoxicity, inflammation, reactive oxygen species generation, endothelial dysfunction, angiogenesis and thrombosis, and thus might influence intracellular signaling pathways that lead to microvascular complications. PPAR alpha has emerged as a novel target to prevent microvascular disease, via both its lipid-related and lipid-unrelated actions. Despite strong experimental evidence of the potential benefits of PPAR alpha agonists in the prevention of vascular damage, the evidence from clinical studies in patients with diabetes mellitus remains limited. Promising findings from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study on microvascular outcomes are countered by elevations in participants' homocysteine and creatinine levels that might potentially attenuate the benefits of PPAR alpha activation. This Review focuses on the role of PPAR alpha activation in diabetic microvascular disease and highlights the available experimental and clinical evidence from studies of PPAR alpha agonists
Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?
No full textApoC-III was discovered almost 50 years ago, but for many years, it did not attract much attention. However, as epidemiological and Mendelian randomization studies have associated apoC-III with low levels of triglycerides and decreased incidence of cardiovascular disease (CVD), it has emerged as a novel and potentially powerful therapeutic approach to managing dyslipidemia and CVD risk. The atherogenicity of apoC-III has been attributed to both direct lipoprotein lipase-mediated mechanisms and indirect mechanisms, such as promoting secretion of triglyceride-rich lipoproteins (TRLs), provoking proinflammatory responses in vascular cells and impairing LPL-independent hepatic clearance of TRL remnants. Encouraging results from clinical trials using antisense oligonucleotide, which selectively inhibits apoC-III, indicate that modulating apoC-III may be a potent therapeutic approach to managing dyslipidemia and cardiovascular disease risk.Peer reviewe
On boundedness and compactness of Toeplitz operators in weighted H-infinity-spaces
No full text[EN] We characterize the boundedness and compactness of Toeplitz operators T-a with radial symbols a in weighted H-infinity-spaces H(v)(infinity)on the open unit disc of the complex plane. The weights v are also assumed radial and to satisfy the condition (B) introduced by the second named author. The main technique uses Taylor coefficient multipliers, and the results are first proved for them. We formulate a related sufficient condition for the boundedness and compactness of Toeplitz operators in reflexive weighted Bergman spaces on the disc. We also construct a bounded harmonic symbol f such that T-f is not bounded in H-v(infinity) for any v satisfying mild assumptions. As a corollary, the Bergman projection is never bounded with respect to the corresponding weighted sup-norms. However, we also show that, for normal weights v, all Toeplitz operators with a trigonometric polynomial as the symbol are bounded on H-v(infinity) . (C) 2020 Elsevier Inc. All rights reserved.The research of Bonet was partially supported by the projects MTM2016-76647-P and GV Prometeo/2017/102 (Spain). The research of Taskinen was partially supported by a research grant from the Faculty of Science of the University of Helsinki.Bonet Solves, JA.; Lusky, W.; Taskinen, J. (2020). On boundedness and compactness of Toeplitz operators in weighted H-infinity-spaces. Journal of Functional Analysis. 278(10):1-26. https://doi.org/10.1016/j.jfa.2019.108456S12627810Bonet, J., Lusky, W., & Taskinen, J. (2018). Solid hulls and cores of weighted H ∞ -spaces. Revista Matemática Complutense, 31(3), 781-804. doi:10.1007/s13163-018-0265-6Bonet, J., Lusky, W., & Taskinen, J. (2019). Solid cores and solid hulls of weighted Bergman spaces. Banach Journal of Mathematical Analysis, 13(2), 468-485. doi:10.1215/17358787-2018-0049Constantin, O., & Peláez, J. Á. (2015). Boundedness of the Bergman projection on Lp-spaces with exponential weights. Bulletin des Sciences Mathématiques, 139(3), 245-268. doi:10.1016/j.bulsci.2014.08.012Dostanić, M. R. (2004). UNBOUNDEDNESS OF THE BERGMAN PROJECTIONS ON SPACES WITH EXPONENTIAL WEIGHTS. Proceedings of the Edinburgh Mathematical Society, 47(1), 111-117. doi:10.1017/s0013091501000190Engliš, M. (2008). Toeplitz operators and weighted Bergman kernels. Journal of Functional Analysis, 255(6), 1419-1457. doi:10.1016/j.jfa.2008.06.026Grudsky, S., & Vasilevski, N. (2001). Bergman-Toeplitz operators: Radial component influence. Integral Equations and Operator Theory, 40(1), 16-33. doi:10.1007/bf01202952Harutyunyan, A., & Lusky, W. (2010). On L1-subspaces of holomorphic functions. Studia Mathematica, 198(2), 157-175. doi:10.4064/sm198-2-4Luecking, D. H. (1987). Trace ideal criteria for Toeplitz operators. Journal of Functional Analysis, 73(2), 345-368. doi:10.1016/0022-1236(87)90072-3Luecking, D. H. (2007). Finite rank Toeplitz operators on the Bergman space. Proceedings of the American Mathematical Society, 136(05), 1717-1724. doi:10.1090/s0002-9939-07-09119-8Lusky, W. (1995). On Weighted Spaces of Harmonic and Holomorphic Functions. Journal of the London Mathematical Society, 51(2), 309-320. doi:10.1112/jlms/51.2.309Lusky, W. (2006). On the isomorphism classes of weighted spaces of harmonic and holomorphic functions. Studia Mathematica, 175(1), 19-45. doi:10.4064/sm175-1-2Lusky, W., & Taskinen, J. (2008). Bounded holomorphic projections for exponentially decreasing weights. Journal of Function Spaces and Applications, 6(1), 59-70. doi:10.1155/2008/217160Lusky, W., & Taskinen, J. (2011). Toeplitz operators on Bergman spaces and Hardy multipliers. Studia Mathematica, 204(2), 137-154. doi:10.4064/sm204-2-3Mannersalo, P. (2016). Toeplitz operators with locally integrable symbols on Bergman spaces of bounded simply connected domains. Complex Variables and Elliptic Equations, 61(6), 854-874. doi:10.1080/17476933.2015.1120293STROETHOFF, K. (1998). Compact Toeplitz operators on Bergman spaces. Mathematical Proceedings of the Cambridge Philosophical Society, 124(1), 151-160. doi:10.1017/s0305004197002375Taskinen, J., & Virtanen, J. (2010). Toeplitz operators on Bergman spaces with locally integrable symbols. Revista Matemática Iberoamericana, 693-706. doi:10.4171/rmi/614Zorboska, N. (2003). Toeplitz operators with BMO symbols and the Berezin transform. International Journal of Mathematics and Mathematical Sciences, 2003(46), 2929-2945. doi:10.1155/s016117120321203
Acquired Liver Fat Is A Key Determinant of Serum Lipid Alterations in Healthy Monozygotic Twins
No full textObjective: The effects of acquired obesity on lipid profile and lipoprotein composition in rare BMI-discordant monozygotic (MZ) twin pairs were studied. Design and Methods: Abdominal fat distribution, liver fat (magnetic resonance imaging and spectroscopy), fasting serum lipid profile (ultracentrifugation, gradient gel-electrophoresis, and colorimetric enzymatic methods), and lifestyle factors (questionnaires and diaries) were assessed in 15 BMI-discordant (within-pair difference [Delta] in BMI >3 kg/m(2)) and nin concordant (Delta BMI <3 kg/m(2)) MZ twin pairs, identified from two nationwide cohorts of Finnish twins. Results: Despite a strong similarity of MZ twins in lipid parameters (intra-class correlations 0.42-0.90, P < 0.05), concentrations of apolipoprotein B (ApoB), intermediate-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein 3a% (HDL3a%), and HDL3c% were higher (P < 0.05) and those of HDL cholesterol, HDL2-C, and HDL2b% were lower (P < 0.01) in the heavier co-twins of BMI-discordant pairs. The composition of lipoprotein particles was similar in the co-twins. When BMI-discordant pairs were further divided into liver fat-discordant and concordant (based on median for Dliver fat, 2.6%), the adverse lipid profile was only seen in those heavy co-twins who also had high liver fat. Conversely, BMI-discordant pairs concordant for liver fat did not differ significantly in lipid parameters. In multivariate analyses controlling for Delta subcutaneous, Delta intra-abdominal fat, sex, Delta smoking and Delta physical activity, Dliver fat was the only independent variable explaining the variation in Delta ApoB, Delta total cholesterol, and Delta LDL-C concentration. Conclusions: Several pro-atherogenic changes in the amounts of lipids but not in the composition of lipoprotein particles were observed in acquired obesity. In particular, accumulation of liver fat was associated with lipid disturbances, independent of genetic effects
Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states
No full textParaoxonase is a high density lipoprotein (HDL) associated enzyme with a hypothesised role in the protection of low density lipoproteins (LDL) from oxidative stress. The present study examined paraoxonase in several genetically distinct HDL deficiency states. Despite reduction or even absence of detectable HDL, enzyme activity was present in sera from A-I-Pisa, A-I- Helsinki, A-I-Milano and Tangier patients. Both enzyme activities and peptide concentrations were modulated (reduced) but specific activities were broadly similar to controls, suggesting an impact on peptide concentration rather than an inhibition of enzyme activity. Despite the absence of HDL in A-I- Pisa and Tangier subjects, there was no association of paraoxonase with very low density lipoproteins or LDL. Paraoxonase function is maintained in HDL deficient states. It implies that certain HDL-associated anti-atherogenic processes may not be entirely compromised by HDL deficiency. This has important implications for the cardiovascular risk associated with modulated HDL concentrations
The K-Step Spatial Sign Covariance Matrix
No full textThe Sign Covariance Matrix is an orthogonal equivariant estimator of mul- tivariate scale. It is often used as an easy-to-compute and highly robust estimator. In this paper we propose a k-step version of the Sign Covariance Matrix, which improves its e±ciency while keeping the maximal breakdown point. If k tends to infinity, Tyler's M-estimator is obtained. It turns out that even for very low values of k, one gets almost the same e±ciency as Tyler's M-estimator.
Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia (Journal of Clinical Endocrinology and Metabolism (2009) 94, (4584-4590))
No full textTriglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab
No full textAims: Guidelines recommend targeting non-high-density lipoprotein cholesterol to reduce cardiovascular risk. We assessed the impact of baseline triglycerides on non-high-density lipoprotein cholesterol goal attainment in 10 phase 3 trials with alirocumab versus control (n = 4983). Methods: Trials were grouped into four pools based on alirocumab dose (75–150 mg every 2 weeks), control (placebo/ezetimibe) and statin use. Baseline triglyceride quintiles were built within each pool. Non-high-density lipoprotein cholesterol goal attainment (very high risk: <100 mg/dl; moderate/high risk: <130 mg/dl), low-density lipoprotein cholesterol goal attainment (very high risk: <70 mg/dl; moderate/high risk: <100 mg/dl) and changes from baseline in lipid parameters were assessed at Week 24 among baseline triglyceride quintiles. Results: Higher baseline triglycerides were associated with a worse cardiovascular risk profile. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol increased with higher triglycerides, but the magnitude in non-high-density lipoprotein cholesterol was three- to four-fold higher compared with the increase in low-density lipoprotein cholesterol. Non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol percentage reductions from baseline with alirocumab were similar regardless of baseline triglycerides. A greater proportion of alirocumab-treated patients attained non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol goals compared with placebo or ezetimibe. Unlike low-density lipoprotein cholesterol goal attainment, non-high-density lipoprotein cholesterol goal attainment significantly declined with increasing baseline triglycerides (p < 0.05 for trend tests). A single standard deviation increase in baseline log(triglycerides) was significantly associated with lower odds ratios of attaining non-high-density lipoprotein cholesterol goals in the different pools and treatment (alirocumab/placebo/ezetimibe) groups, unlike low-density lipoprotein cholesterol goal attainment. Conclusion: Individuals with increased triglycerides have higher non-high-density lipoprotein cholesterol levels and lower rates of non-high-density lipoprotein cholesterol goal attainment (unlike low-density lipoprotein cholesterol goal attainment). Alirocumab improves non-high-density lipoprotein cholesterol goal attainment in this population. These results highlight the impact of triglycerides on non-high-density lipoprotein cholesterol and the need for novel therapies targeting triglyceride-related pathways
- …
